Tag
JAK inhibitors, proven in rheumatoid arthritis, show potential in extending surgical-free intervals and reducing dilation frequency in idiopathic subglottic stenosis by targeting immune-mediated fibroinflammation.
Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.
This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.
The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu
The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus